Result (English)

Paper

• Fuyama K, Ogawa M, Mizusawa J, Kanemitsu Y, Fujita S, Kawahara T, Sakamaki K, Oba K. Impact of correlations between prioritized outcomes on the net benefit and its estimate by generalized pairwise comparisons. Stat Med. 2023 Feb 27. doi: 10.1002/sim.9690. Online ahead of print.
• Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, Onizuka M, Yokose N, Fujimaki K, Hagihara M, Oshikawa G, Murayama K, Kumagai T, Kimura S, Najima Y, Iriyama N, Tsutsumi I, Oba K, Kojima H, Sakamaki H, Inokuchi K; Kanto CML Study Group. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study. Int J Hematol. 2023 Feb 4. doi: 10.1007/s12185-023-03549-3. Online ahead of print.
• Yamashina A, Nishikori M, Fujimito H, Oba K. Identification of predictive factors interacting with heart rate reduction for potential beneficial clinical outcomes in chronic heart failure: A systematic literature review and meta-analysis. Int J Cardiol Heart Vasc 2022;43:101141.
• Noguchi T, Ishihara S, Uchino M, Ikeuchi H, Okabayashi K, Futami K, Tanaka S, Ohge H, Nagahara H, Watanabe K, Itabashi M, Okamoto K, Okita Y, Mizushima T, Mizuuchi Y, Yamada K, Shimada Y, Sato Y, Kimura H, Takahashi K, Hida K, Kinugasa Y, Okuda J, Daito K, Koyama F, Ueno H, Yamamoto T, Hanai T, Maemoto A, Oba K, Ajioka Y, Sugihara K; Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers by the Japanese Society for Cancer of the Colon, Rectum. Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn's disease. J Gastroenterol 2023;58(1):14-24.
• Izumi S, Hagiwara Y, Matsuyama Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L. Health Qual Life Outcomes. 2023;21:3.
• Okada A, Yamada G, Kimura T, Hagiwara Y, Yamaguchi S, Kurakawa KI, Nangaku M, Yamauchi T, Matsuyama Y, Kadowaki T. Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities. J Diabetes Investig. 2022. https://doi.org/10.1111/jdi.13966 Online ahead of print.
• Matsumoto H, Hagiwara Y, Yamamoto-Mitani N, Igarashi A. A randomized control trial for ReDeSign: A dementia-friendly mobile microlearning training for store workers in Japan. Gerontologist. 2022 Dec 12;gnac182. doi: 10.1093/geront/gnac182. Online ahead of print.
• Takeuchi Y, Iwagami M, Ono S, Michihata N, Uemura K, Yasunaga H. A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan. Vaccine. 40(52) 7622-7630 2022 Dec.
• The Fact-finding Committee of the Japanese Society of Pressure Ulcers, Konya C, Takeuchi Y, Nakagami G, Kitamura A, Morita K, Ishizawa M, Abe Y, Higuchi H, Mizuki T, Motegi S, Shoju S, Shimada K, Tanaka K, Kawakami S, Sanada H. Nationwide time-series surveys of pressure ulcer prevalence in Japan. Journal of Wound Care. 31(Sup12) S40-S47 2022 Dec.
• Kikawa Y, Hagiwara Y, Fujisawa T, Araki K, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Toyama T, Aihara T, Mukai H, Taira N. Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy. PLoS One. 2022;17:e0278344.

> Read more

Conference

• Kumamaru H, Takeuchi Y, Kohsaka S, Matsui H, Yasunaga H, Miyata H. Comparative effectiveness of First-line SGLT2 inhibitor use on heart failure hospitalization among patients with type 2 diabetes mellitus; A target trial emulation (Poster presentation). 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 2022 Aug, Copenhagen/Online.
• Takeuchi Y, Iwagami M, Ono S, Yasunaga H. Serious adverse effects after COVID-19 vaccination in Japan: Analysis using administrative claims data linked with vaccination registry. 14th Asian Conference on Pharmacoepidemiology. 2022 Oct, Tainan/Online.
• Sawamoto R, Matsuyama Y. Standardized mortality ratio-weighted power prior approach for covariate-adjusted borrowing of historical control data. 2021 Joint Statistical Meetings, Online. Aug 2021.
• Takeuchi Y, Hagiwara Y, Matsuyama Y. Marginal structural Cox models in nested case-control studies with time-varying treatments. 42nd Conference of the International Society for Clinical Biostatistics. Online. Jul 2021.
• Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
• Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
• Takeuchi Y. Kumamaru H, Hagiwara Y, Matsui H, Yasunaga H, Miyata H, Matsuyama Y, Risk of Sodium-Glucose Cotransporter-2 Inhibitor on the Incidence of Urinary Tract Infection among Diabetic Patients in Japan: A Nationwide Cohort Study (poster presentation). ICPE All Access. Online. Sep 2020.
• Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? An answer from a missing data perspective. International Society for Pharmacoeconomics and Outcome Research Europe 2019. Copenhergen, Denmark. November 2019. PNS323.
• Kashiwabara K, Matsuyama Y. Treatment effect estimation in an efficient adaptive design: comparison with the exact estimation method. 40th Annual Conference of the ISCB 2019, 14-18 July, Leuven, Belgium.
• Satoi S, Unno M, Motoi F, Matsuyama Y, Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, Yoshitomi H, Takahashi S, Sho M, Ueno H, Yamamoto H, Kosuge T. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (Randomized phase II/III trial; Prep-02/JSAP-05). ASCO 2019, May 31-June 4, Chicago, USA

> Read more

Symposium

• Yutaka Matsuyama. Measuring PROs for people with Parkinson’s in clinical trials. Takeda Expert Conference on Parkinson’s Disease. Tokyo. 2020/12/12.
• Hagiwara Y. Estimation of modified effectiveness in confirmatory cancer clinical trials using dynamic marginal structural models. PeSeTo International Symposium on Public Health 2016, Tokyo, Japan, March 15, 2016.
• Takeuchi Y. The Project of Medical Information Database Infrastructure for Post-Marketing Drug Safety in Japan. CRT 2016. Washington DC. Feb 2016.
• Takeuchi Y. PMDA’s Activities Promoting Pharmaco-Epidemiological Safety Assessment (MIHARI & MID-NET Initiatives). 12th Annual Meeting DIA JAPAN 2015. Tokyo. Nov 2015.
• Shinozaki T, Matsuyama Y. (November 2014). “Doubly robust estimation of a marginal structural model in the exposed population.” At: Kyoto International Conference on Modern Statistics in the 21st Century, Kyoto, Japan. Chair: Manabu Iwasaki. (Invited)
• Takeuchi Y. Strategies for Reinforcing and Enhancing the Post-Marketing Safety Measures in Japan. DIA Pharmacovigilance and Risk Management Strategies 2014. Washington DC. Jan 2014.
• Matsuyama Y. Semiparametric estimation of treatment effect in a randomized clinical trial with missing data. International Symposium Incomplete Data Analysis and Causal Inference, Osaka University, 22-23 September 2013.
• Matsuyama Y and Tanaka Y. Estimation of treatment effect adjusting for non-compliance using the intensity score method. 科学研究費補助金（基盤研究 (A) (1)）シンポジウム「不完全データ解析とその周辺」 東京．2006/1/23.

> Read more

Publication

• Oba K, Kuchiba A. Sample Size Calculations for Phase III Trials in Oncology. In: Halabi S, Michiels S (Eds.) Textbook of Clinical Trials in Oncology: A Statistical Perspective. CRC Press, FL, 2019
• Shinozaki T, Matsuyama Y. Data analysis on real world data: an overview. In: Sudoh, O. (editor). Epidemiologic Research on Real World Medical Data in Japan. Switzerland: Springer International Publishing, 2019 (forthcoming).
• Oba K, Paoletti X. Evaluation of Surrogate Endpoints using a Meta-Analysis Approach with Individual Patient Data: Summary of a Gastric Cancer Meta-Analysis Project. In: Matsui S, Crowley J(Eds.) Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, Singapore, 2017
• Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A,Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints in cancer clinical trials. In: Oncology Clinical Trials: Successful Design, Conduct and Analysis. Second Edition, Demos Medical Publishing, NY, 2017

> Read more

TOP